Mednax, Inc (NYSE:MD) issued an update on its fourth quarter earnings guidance on Wednesday morning. The company provided earnings per share guidance of $0.80-0.85 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.85.

A number of equities research analysts have recently issued reports on the stock. Jefferies Group LLC reaffirmed a hold rating and issued a $53.00 price objective (up previously from $50.00) on shares of Mednax in a research note on Thursday, July 6th. BidaskClub cut shares of Mednax from a hold rating to a sell rating in a research note on Friday, July 28th. Mizuho reaffirmed a neutral rating and issued a $48.00 price objective (down previously from $62.00) on shares of Mednax in a research note on Tuesday, August 1st. Robert W. Baird reaffirmed a hold rating and issued a $47.00 price objective on shares of Mednax in a research note on Sunday, September 3rd. Finally, KeyCorp set a $51.00 price objective on shares of Mednax and gave the company a buy rating in a research note on Wednesday. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and two have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus target price of $55.44.

Mednax (NYSE:MD) last posted its quarterly earnings data on Wednesday, November 1st. The company reported $0.87 EPS for the quarter, hitting the consensus estimate of $0.87. The company had revenue of $868.95 million during the quarter, compared to analyst estimates of $864.78 million. Mednax had a net margin of 8.78% and a return on equity of 11.89%. Mednax’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.09 earnings per share.

In other news, insider John C. Pepia sold 3,000 shares of the business’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total transaction of $128,550.00. Following the completion of the sale, the insider now directly owns 35,569 shares of the company’s stock, valued at $1,524,131.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.40% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This piece was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.